2401 2nd Street N
ALZYN is an early stage company committed to reducing the tragedy of Alzheimer's. The Company is pursuing a unique and promising approach to halting the progression of AD. The science, licensed from the Florida State Science Foundation, is at a preclinical development stage. ALZYN is being advised by the Newport Board Group.
Managing Director: Don Rosenkoetter.